Immunogenicity Testing of Medicilon

Immunogenicity testing is focused on the detection and characterization of anti-drug antibodies (ADAs) and the determination whether these ADAs are neutralizing antibodies(NABs), as NABs may affect the pharmacokinetics (PK) of the drug. It is clear however that animal studies are not considered relevant to predict immunogenicity in humans. Still, the selection of the mini-pig to explore their possibilities for immunogenicity testing of biopharmaceuticals, especially to assist in the interpretation of safety studies, is based on the improved knowledge that various physiological aspects of Göttingen Minipigs® resemble more the human situation than other animal species. It is expected therefore that in the near future the safety testing, including immunogenicity testing of biopharmaceuticals in mini-pigs will increase as an alternative for non human primate studies, which use will be limited or restricted.

Immunogenicity Services

Screening assays for detection of positive samples for Anti-Drug Antibodies (ADA)
Confirmatory assays for ruling out false positive results
Characterization assays to determine the avidity and the isotypes of ADA
Neutralizing assays to assess the drug function inhibition capabilities of ADA
Cellular immune response assays to study the cellular immunogenicity

Immunogenicity Techniques

> Immunoassays:

Electrochemiluminiscence (ECLA / Meso Scale Discovery)
Radioimmunoassay (RIA)
Enzyme-linked immunosorbent assay (ELISA)

> Cell-based Assays:

• Fluorescence and luminescence
• Flow cytometry

> Label-free Interaction Analysis

• Surface plasmon resonance (SPR / Biacore)

Challenges in Immunogenicity Assay

Matrix Interference

Drug Interference

– Many of the therapeutic drugs, particularly an antibody therapeutic, have a long half-life (typically 10-20 days) and often administered chronically at high dose levels without a drug wash-out period.
– Immunogenicity assessments to such therapeutics pose unique challenges in clinical trials especially when significant drug interference is encountered.
– Free drug can complex with anti-drug antibodies directly interferes with the assay.
– Tolerance of the ADA assay for presence of drug to be determined.

Target Interference

– Target interference is also a big concern in bridging immunoassays, especially when target is a soluble receptor.

– Target interference can also be intensified by AD which then release target from target-drug complex.

Our team developed custom bridging assays for new materials that were introduced into the manufacturing processes, to determine their individual immunogenicity profiles. We also re-validated the prior assays with a new positive control that was comparable to the altered biotherapeutic. We then compared the results from these newly validated assays to those from the previous assays to measure any changes in the immunogenicity risk profile of the therapeutic.

Contact Us

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips: Above is part of immunogenicity testing and immunogenicity assay. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

Medicilon Immunogenicity Test Service

Immunogenicity Testing of Medicilon

Factors Affecting the Immunogenicity of Biological Drugs

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

What is Toxicokinetics?

Toxicokinetics is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms toxicokinetics , pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...

阅读全文

Shanghai Medicilon Inc.

搜索此博客